Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals

References

• ConteducaVSansonnoDRussiSPavoneFDammaccoFTherapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agentsJ Infect201468112024012819
   PubMed Web of Science ®Google Scholar
• SuppiahVMoldovanMAhlenstielGInterleukin 28B is associated with response to Hepatitis C interferon-alpha and ribavirin therapyNat Genet20094111100110419749758
   PubMed Web of Science ®Google Scholar
• TanakaYNishidaNSugiyamaMGenome-wide association of Interleukin 28B with response to interferon alpha and ribavirin therapy for chronic hepatitis CNat Genet200941101105110919749757
   PubMed Web of Science ®Google Scholar
• GeDFellayJThompsonAJGenetic variation in interleukin 28B predicts hepatitis C treatment-induced viral clearanceNature2009461726239940119684573
   PubMed Web of Science ®Google Scholar
• RauchAKutalikZDescombesPGenetic variation in interleukin 28B is associated with chronic hepatitis C and treatment failure: genome-wide association studyGastroenterology201013841338134520060832
   PubMed Web of Science ®Google Scholar
• FellayJThompsonAJGeDITPA gene variants protect against anemia in patients treated for chronic hepatitis CNature2010464728740540820173735
   PubMed Web of Science ®Google Scholar
• SakamotoNTanakaYNakagawaMITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis CHepatol Res201040111063107120977565
   PubMed Web of Science ®Google Scholar
• BarrittAS4thFriedMWMaximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virusGastroenterology201214261314132322537438
   PubMed Web of Science ®Google Scholar
• SadlerMDLeeSSRevolution in hepatitis C antiviral therapyBr Med Bull20151131314425680808
   PubMed Web of Science ®Google Scholar
• ReinDBWittenbornJSSmithBDLiffmannDKWardJWThe cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virusClin Infect Dis201561215716825778747
   PubMed Web of Science ®Google Scholar
• Silva-VidalKVMéndez-SánchezNThe good, the bad and the ugly of the new treatments for hepatitis C virusAnn Hepatol201413557457525152995
   PubMed Web of Science ®Google Scholar
• OlmedoDBCaderSAPortoLCIFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitorsJ Med Virol201587101702171525970604
   PubMed Web of Science ®Google Scholar
• CookeGSLemoineMThurszMViral hepatitis and the Global Burden of Disease: a need to regroupJ Viral Hepat201320960060123910643
   PubMed Web of Science ®Google Scholar
• SzaboSMBibbyMYuanYThe epidemiologic burden of hepatitis C virus infection in Latin AmericaAnn Hepatol201211562363522947522
   PubMed Web of Science ®Google Scholar
• Alvarado-MoraMVPinhoJREpidemiological update of hepatitis B, C and delta in Latin AmericaAntivir Ther2013183 Pt B42943323792375
   PubMed Web of Science ®Google Scholar
• FlichmanDMBlejerJLLivellaraBIPrevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodefi-ciency virus in Argentine blood donorsBMC Infect Dis20141421824755089
   PubMed Web of Science ®Google Scholar
• KershenobichDRazaviHASánchez-AvilaJFTrends and projections of hepatitis C virus epidemiology in Latin AmericaLiver Int201131Suppl 21829
   PubMed Web of Science ®Google Scholar
• PanduroARomanSNeed of righteous attitudes towards eradication of hepatitis C virus infection in Latin AmericaWorld J Gastroenterol201622225137514227298556
   PubMed Web of Science ®Google Scholar
• PereiraLMMartelliCMMoreiraRCPrevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional studyBMC Infect Dis2013136023374914
   PubMed Web of Science ®Google Scholar
• FerreiraPRBrandão-MelloCEEstesCDisease burden of chronic hepatitis C in BrazilBraz J Infect Dis201519436336826051505
   PubMed Web of Science ®Google Scholar
• RidruejoEBessoneFDaruichJRHepatitis C virus infection in Argentina: burden of chronic diseaseWorld J Hepatol201681564965827239258
   PubMedGoogle Scholar
• Lozano-SepulvedaSBryan-MarrugoOMerino-MascorroJRivas-EstillaAMApproachability to the new anti-HCV direct acting antiviral agents in the Latin American contextFuture Virol20161113946
   Web of Science ®Google Scholar
• BruggmannPBergTØvrehusALHistorical epidemiology of hepatitis C virus (HCV) in selected countriesJ Viral Hepat201421Suppl 153324713004
   PubMed Web of Science ®Google Scholar
• RazaviHWakedISarrazinCThe present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigmJ Viral Hepat201421Suppl 1345924713005
   PubMed Web of Science ®Google Scholar
• HatzakisAChulanovVGadanoACThe present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm – volume 2J Viral Hepat201522Suppl 1264525560840
   PubMed Web of Science ®Google Scholar
• MessinaJPHumphreysIFlaxmanAGlobal distribution and prevalence of hepatitis C virus genotypesHepatology2015611778725069599
   PubMed Web of Science ®Google Scholar
• SutharABHarriesADA public health approach to hepatitis C control in low- and middle-income countriesPLoS Med2015123e100179525757228
   PubMed Web of Science ®Google Scholar
• Méndez-SánchezNParanáRCheinquerHLatin American Association for the Study of the Liver recommendations on treatment of hepatitis CAnn Hepatol201413Suppl 2s4s66
   Google Scholar
• Sánchez-ÁvilaJFDehesa-ViolanteMMéndez-SánchezNMexican consensus on the diagnosis and management of hepatitis C infectionAnn Hepatol201514Suppl 154825983318
   PubMedGoogle Scholar
• BoteroRCTagleMNew therapies for hepatitis C: Latin American perspectivesClin Liv Dis201551810
   Google Scholar
• AASLD/IDSA HCV Guidance PanelHepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virusHepatology201562393295426111063
   PubMed Web of Science ®Google Scholar
• ThomasDLThioCLMartinMPGenetic variation in IL28B and spontaneous clearance of hepatitis C virusNature2009461726579880119759533
   PubMed Web of Science ®Google Scholar
• Prokunina-OlssonLMuchmoreBTangWA variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virusNat Genet201345216417123291588
   PubMed Web of Science ®Google Scholar
• AkaPVKuniholmMHPfeifferRMAssociation of the IFNL4-ΔG allele with impaired spontaneous clearance of hepatitis C virusJ Infect Dis2014209335035423956438
   PubMed Web of Science ®Google Scholar
• Gonzalez-AldacoKRebello PinhoJRRomanSAssociation with spontaneous hepatitis C viral clearance and genetic differentiation of IL28B/IFNL4 haplotypes in populations from MexicoPLoS One2016111e014625826741362
   PubMed Web of Science ®Google Scholar
• MangiaAThompsonAJSantoroRAn IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic responseGastroenterology2010139382182720621700
   PubMed Web of Science ®Google Scholar
• SarrazinCSusserSDoehringAImportance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patientsJ Hepatol201154341542121112657
   PubMed Web of Science ®Google Scholar
• RallonNINaggieSBenitoJMAssociation of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patientsAIDS2010248F23F2920389235
   PubMed Web of Science ®Google Scholar
• MangiaAThompsonAJSantoroRLimited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoringHepatology201154377278021626525
   PubMed Web of Science ®Google Scholar
• LiYYangLShaKLiuTZhangLCorrelation of interferon-lambda 4 ss469415590 with the hepatitis C virus treatment response and its comparison with interleukin 28b polymorphisms in predicting a sustained virological response: a meta-analysisInt J Infect Dis201653525827810523
   PubMed Web of Science ®Google Scholar
• MuirAJGongLJohnsonSGClinical Pharmacogenetics Implementation Consortium (CPIC)Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimensClin Pharmacol Ther201495214114624096968
   PubMed Web of Science ®Google Scholar
• SerfatyLHow to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antiviralsLiver Int201535Suppl 1182025529083
   PubMed Web of Science ®Google Scholar
• MeissnerEGBonDProkunina-OlssonLIFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirinJ Infect Dis2014209111700170424367041
   PubMed Web of Science ®Google Scholar
• AkamatsuSHayesCNOchiHAssociation between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5AJ Hepatol201563355456325849245
   PubMed Web of Science ®Google Scholar
• ItakuraJKurosakiMTakadaHNaturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapyHepatol Res20154510E115E12125564756
   PubMed Web of Science ®Google Scholar
• PeifferKHSommerLSusserSInterferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3Hepatology2016631637326406534
   PubMed Web of Science ®Google Scholar
• StättermayerAFScherzerTBeinhardtSRutterKHoferHFerenciPReview article: genetic factors that modify the outcome of viral hepatitisAliment Pharmacol Ther201439101059107024654629
   PubMed Web of Science ®Google Scholar
• TanakaYKurosakiMNishidaNGenome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis CHum Mol Genet201120173507351621659334
   PubMed Web of Science ®Google Scholar
• ThompsonAFellayJPatelKVariants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reductionGastroenterology201013941181118920547162
   PubMed Web of Science ®Google Scholar
• D’AvolioACusatoJDe NicolòAAllegraSDi PerriGPharmacogenetics of ribavirin-induced anemia in HCV patientsPharmacogenomics201617892594127248282
   PubMed Web of Science ®Google Scholar
• KurosakiMTanakaYNishidaNModel incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis CJ Med Virol201385344945823297176
   PubMed Web of Science ®Google Scholar
• AkamatsuSHayesCNTsugeMRibavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphismJ Viral Hepat201522216617424930407
   PubMed Web of Science ®Google Scholar
• ReichDPattersonNCampbellDReconstructing native American population historyNature2012488741137037422801491
   PubMed Web of Science ®Google Scholar
• FridmanCGonzalezRSPereiraACCardenaMMHaplotype diversity in mitochondrial DNA hypervariable region in a population of southeastern BrazilInt J Legal Med2014128458959324846100
   PubMed Web of Science ®Google Scholar
• CorachDLaoOBobilloMCInferring continental ancestry of argentineans from autosomal, Y-chromosomal and mitochondrial DNAAnn Hum Genet2010741657620059473
   PubMed Web of Science ®Google Scholar
• de Saint PierreMBraviCMMottiJAn alternative model for the early peopling of southern South America revealed by analyses of three mitochondrial DNA haplogroupsPLoS One201279e4348622970129
   PubMed Web of Science ®Google Scholar
• HeinzTCárdenasJMÁlvarez-IglesiasVThe genomic legacy of the transatlantic slave trade in the yungas valley of BoliviaPLoS One2015108e013412926263179
   PubMed Web of Science ®Google Scholar
• SandovalJRLacerdaDRAcostaOThe genetic history of peruvian quechua-lamistas and chankas: uniparental DNA patterns among autochthonous Amazonian and Andean PopulationsAnn Hum Genet20168028810126879156
   PubMed Web of Science ®Google Scholar
• CárdenasJMHeinzTPardo-SecoJThe multiethnic ancestry of Bolivians as revealed by the analysis of Y-chromosome markersForensic Sci Int Genet20151421021825450796
   PubMed Web of Science ®Google Scholar
• González-SobrinoBZPintado-CortinaAPSebastián-MedinaLGenetic diversity and differentiation in Urban and Indigenous populations of Mexico: patterns of mitochondrial DNA and Y-chromosome lineagesBiodemography Soc Biol2016621537227050033
   PubMed Web of Science ®Google Scholar
• HomburgerJRMoreno-EstradaAGignouxCRGenomic insights into the ancestry and demographic history of South AmericaPLoS Genet20151112e100560226636962
   PubMed Web of Science ®Google Scholar
• HeinzTAlvarez-IglesiasVPardo-SecoJAncestry analysis reveals a predominant Native American component with moderate European admixture in BoliviansForensic Sci Int Genet20137553754223948324
   PubMed Web of Science ®Google Scholar
• VulloCGomesVRomaniniCAssociation between Y haplogroups and autosomal AIMs reveals intra-population substructure in Bolivian populationsInt J Legal Med2015129467368024878616
   PubMed Web of Science ®Google Scholar
• AltshulerDMGibbsRAPeltonenLInternational HapMap 3 ConsortiumIntegrating common and rare genetic variation in diverse human populationsNature20104677311525820811451
   PubMed Web of Science ®Google Scholar
• Suarez-KurtzGPharmacogenetics in the brazilian populationFront Pharmacol2010111821833165
   PubMed Web of Science ®Google Scholar
• DelvauxNCostaVDCostaMMInosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis CMem Inst Oswaldo Cruz2015110563664326154744
   PubMed Web of Science ®Google Scholar
• RidruejoESolanoAMarcianoSGenetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirinAnn Hepatol201110445245721911885
   PubMed Web of Science ®Google Scholar
• VenegasMVillanuevaRAGonzalezKBrahmJIL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patientsWorld J Gastroenterol201117313636363921987611
   PubMed Web of Science ®Google Scholar
• FerreiraPRSantosCCortesRAssociation between IL28B gene polymorphisms and sustained virological response in patients coinfected with HCV and HIV in BrazilJ Antimicrob Chemother201267250951022146876
   PubMed Web of Science ®Google Scholar
• Martinez-GomezLEChavez-TapiaNCBurguete-GarciaAIIL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican populationAnn Hepatol201211687688123109451
   PubMed Web of Science ®Google Scholar
• AlvesCFGrottCSLungeVRInterferon lambda 4 (IFNL4) gene polymorphism is associated with spontaneous clearance of HCV in HIV-1 positive patientsGenet Mol Biol201639337437927560987
   PubMed Web of Science ®Google Scholar
• Sixtos-AlonsoMSAvalos-MartinezRSandoval-SalasRA genetic variant in the interleukin 28B gene as a major predictor for sustained virologic response in chronic hepatitis C virus infectionArch Med Res201546644845326189761
   PubMed Web of Science ®Google Scholar
• GalvanCAElbarchaOCFernandezEJBeltramoDMSoriaNWDistribution of polymorphisms in cytochrome P450 2B6, histocompatibility complex P5, chemokine coreceptor 5, and interleukin 28B genes in inhabitants from the central area of ArgentinaGenet Test Mol Biomarkers201216213013321854194
   PubMed Web of Science ®Google Scholar
• SozaALopez-LastraMIL28B Polymorphisms among Latin American HCV patientsCurr Hepatitis Rep2013124276279
   Google Scholar
• TrinksJHulaniukMLCaputoMDistribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed populationPharmacogenomics J201414654955424841973
   PubMed Web of Science ®Google Scholar
• TrinksJHulaniukMLCaputoMDistribución de polimorfismos de nucleótido simple (SNPs) predictores de la respuesta al tratamiento antiviral en la infección crónica por el virus de la hepatitis C (HCV) en las distintas regiones geográficas de Argentina [Distribution of single-nucleotide polymorphisms (SNPs) predictive of antiviral treatment response in hepatitis C virus (HCV) chronic infection in different geographic regions in Argentina]Medicina (B Aires)201474Suppl 3S117S118 Spanish
   Google Scholar
• CavalcanteLNAbe-SandesKAngeloALIL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed populationLiver Int201232347648622098416
   PubMed Web of Science ®Google Scholar
• de Seixas Santos NastriACde Mello MaltaFDinizMAAssociation of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern BrazilArch Virol201616161477148426973228
   PubMed Web of Science ®Google Scholar
• ChidiAPRogalSBryceCLCost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis CHepatology201663242843626524695
   PubMed Web of Science ®Google Scholar
• NajafzadehMAnderssonKShrankWHCost-effectiveness of novel regimens for the treatment of hepatitis C virusAnn Intern Med2015162640751925775313
   PubMed Web of Science ®Google Scholar
• EdwardsDJCoppensDGPrasadTLRookLAIyerJKAccess to hepatitis C medicinesBull World Health Organ2015931179980526549908
   PubMed Web of Science ®Google Scholar
• ChuTWKulkarniRGaneEJEffect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis CGastroenterology2012142479079522248659
   PubMed Web of Science ®Google Scholar
• MontoARyanJIs IL28B genotype associated with more than one aspect of viral clearance?Hepatology20125662414241623212777
   PubMedGoogle Scholar
• European Association for the Study of the LiverEASL Practice Guidelines: management of hepatitis C virus infectionJ Hepatol201460239242024331294
   PubMed Web of Science ®Google Scholar
• Italian Association for the Study of the Liver (AISF)Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF)Dig Liver Dis2014461182424119482
   PubMedGoogle Scholar
• PearlmanBLEhlebenCHepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitorHepatology2014591717723873583
   PubMed Web of Science ®Google Scholar
• AndriulliANardiADi MarcoVAn a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis CDig Liver Dis201446981882524953209
   PubMedGoogle Scholar